scorecardresearch
Add as a preferred source on Google
Friday, May 1, 2026
TopicAnti-cancer drugs

Topic: anti-cancer drugs

SC declines to restrain Zydus from selling cancer drug biosimilar, tells Bristol Myers to approach HC

A bench headed by the Chief Justice of India suggests Squibb to conduct a mapping exercise of Zydus product with their claimed patent to ascertain infringement, if any.

Budget cuts import costs of certain cancer & rare disease drugs. Why it offers little relief to patients

Cancer imposes catastrophic health expenditure in India, with medicines constituting over 60% of out-of-pocket expenditure. Research shows wide price variations, limited cost containment.

Drug costs form chunk of out-of-pocket spending on health in India. This could change with GST reforms

The Union Finance Ministry announced a five percent GST on all drugs and medicines from 22 September—down from the earlier 12 percent GST.

PGIMER report bats for new-age targeted lung cancer therapies to be included in AB-PMJAY

Report commissioned by govt analysed cost-effectiveness of 2 medicines, comparing them to to chemo in patients with newly diagnosed advanced or metastatic non-small cell lung cancer.

Months after import duty waiver, GST slashed on same 3 anti-cancer drugs. Why this is little relief

Centre moves to reduce costs of trastuzumab deruxtecan, osimertinib & durvalumab, all 3 by British-Swedish pharma giant AstraZeneca. Doctors seek exemptions for more such drugs. 

On Camera

India’s real estate will meet the reality of agentic AI

New Delhi: The outsourcing industry, India’s largest white-collar employer, is a juggernaut that has all but stopped moving. The dollar revenue at the top...

Adani’s giant copper plant hits technical setbacks in first year

The 500,000 tonne-per-year plant produced just 94,000 tonnes of refined copper from April 2025 to February this year.

Indian drone tech company ideaForge signs MoU with Japanese firm to develop next-gen AI powered drones

By pairing Indian drone engineering with Japanese semiconductor expertise, the two firms aim to develop more advanced autonomous systems tailored to both defence & commercial use.

Trump, Netanyahu’s Iran gamble: The regime change rebound

American objectives are unmet. They neither have muscle nor motivation to resume the war. As for Iran, the regime didn’t just survive, it’s now led by more radical individuals.